Blog
RSS FeedPosted by Michael Wonder on 01 Jun 2020
Canada's new drug price rules pushed to next year
1 June 2020 - Canada's drug pricing agency said on Monday that new regulations aimed at lowering costs would come ...
Posted by Michael Wonder on 28 May 2020
Tax payers paid to develop remdesivir but will have no say when Gilead sets the price
27 May 2020 - Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus ...
Posted by Michael Wonder on 28 May 2020
Australia avoids 'risky business' of coronavirus vaccine sweepstakes
27 May 2020 - Australia is avoiding huge financial risks by staying out of the global sweepstakes on coronavirus vaccines. ...
Posted by Michael Wonder on 27 May 2020
FDA grants priority review of Nucala for patients with hypereosinophilic syndrome
27 May 2020 - An approval would give Nucala a third indication in an eosinophil driven disease. ...
Posted by Michael Wonder on 27 May 2020
Trump tries to convince voters he’s lowered drug prices, based only on a modest tweak to Medicare
26 May 2020 - President Trump used a glitzy Rose Garden address, flanked by pharmaceutical company CEOs and patient advocates, ...
Posted by Michael Wonder on 27 May 2020
COVID-19: UK authorises anti-viral drug remdesivir
26 May 2020 - A drug treatment called remdesivir that appears to shorten recovery time for people with coronavirus is ...
Posted by Michael Wonder on 27 May 2020
Record flu vaccines in 2020 to protect Australians
27 May 2020 - An additional two million flu vaccines will available from this week bringing the total number available in ...
Posted by Michael Wonder on 27 May 2020
Prospective dialogue between developers and regulators makes for better evidence generation
27 May 2020 - EMA, in collaboration with other parties, has recently published two scientific articles outlining the importance of ...
Posted by Michael Wonder on 27 May 2020
Bristol Myers Squibb receives European Commission approval for Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease
27 May 2020 - Zeposia is the only approved sphingosine-1-phosphate receptor modulator for RRMS patients with active disease. ...
Posted by Michael Wonder on 27 May 2020
NICE issues final guidance on NHS use of Bayer's Vitrakvi
27 May 2020 - The NICE has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety ...
Posted by Michael Wonder on 27 May 2020
NICE recommends treatment for type of small-cell lung cancer
27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE. ...
Posted by Michael Wonder on 27 May 2020
EMA publishes agenda for 25-28 May 2020 CHMP meeting
27 May 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 27 May 2020
EMA commissions independent research to prepare for real world monitoring of COVID-19 vaccines
27 May 2020 - EMA is engaging early with researchers to ensure that a European infrastructure will be in place to ...
Posted by Michael Wonder on 27 May 2020
U.S. FDA approves Opdivo (nivolumab) and Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer
26 May 2020 - Approval marks sixth indication for Opdivo and Yervoy-based combinations across five types of cancer. ...
Posted by Michael Wonder on 27 May 2020
Cellectar receives FDA fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia
26 May 2020 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in lymphoplasmacytic ...
Posted by Michael Wonder on 27 May 2020
Alnylam announces U.S. FDA has granted priority review of the lumasiran new drug application for the treatment of primary hyperoxaluria type 1
26 May 2020 - PDUFA date set for 3 December 2020. ...